The progression of coronary atherosclerosis was assessed by repeat angiography in 28 patients and 20 controls with hyperlipidaemia (serum cholesterol concentration > 7-2 mmol/l (278 mg/100 ml) or serum triglyceride concentration > 20 mmol/l (177 mg/100 ml), or both) and symptomatic coronary artery disease of two or three vessels. By ali criteria coronary lesions progressed significantly less in the patients than the controls: the angiographic state remained completely unchanged in nine (32%) of the patients compared with only one (8%) of the surviving controls; of the arterial segments at risk, 46 (16-5%) progressed in the patients compared with 50 (38 2%) in the controls (p <0 001); and the coronary obstruction increased less in patients than in controls (p <0 05). Cardiac survival was 89% in seven years in the patients compared with 65% in five years in the controls (p <0-01). The anginal symptoms diminished or remained stable in 16 of the 24 patients who survived until the end of the study.
Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study ESKO A NIKKILA, PERTTI VIIKINKOSKI, MATTI VALLE, M H FRICK Abstract The progression of coronary atherosclerosis was assessed by repeat angiography in 28 patients and 20 controls with hyperlipidaemia (serum cholesterol concentration > 7-2 mmol/l (278 mg/100 ml) or serum triglyceride concentration > 20 mmol/l (177 mg/100 ml), or both) and symptomatic coronary artery disease of two or three vessels. Twenty eight patients (26 men and two women) were treated with diet and drugs (clofibrate or nicotinic acid, or both) to lower lipid concentrations. Twenty men taking part in a simultaneous study served as non-randomised controls. They received medical treatment for coronary artery disease but no treatment to reduce lipid concentrations. The initial levels of coronary risk factors and the angiographic state were comparable in the two groups. In the 28 patients total cholesterol, total triglyceride, and low density lipoprotein cholesterol concentrations were reduced by an average 18%, 38%, and 19% respectively by treatment for hyperlipidaemia and high density lipoprotein cholesterol concentration was increased on average by 10%. The treatment maintained these concentrations during a follow up of seven years.
By ali criteria coronary lesions progressed significantly less in the patients than the controls: the angiographic state remained completely unchanged in nine (32%) of the patients compared with only one (8%) of the surviving controls; of the arterial segments at risk, 46 (16-5%) progressed in the patients compared with 50 (38 2%) in the controls (p <0 001); and the coronary obstruction increased less in patients than in controls (p <0 05). Cardiac survival was 89% in seven years in the patients compared with 65% in five years in the controls (p <0-01). The anginal symptoms diminished or remained stable in 16 of the 24 patients who survived until the end of the study. total cholesterol concentration exceeding 7-2 mmol/l (278 mg/100 Ml) or serum triglyceride concentration exceeding 2-0 mmol/l (177 mg/ 100 ml), or both, were eligible. Patients considered for surgical treatment and those with clinical diabetes, poor left ventricular function, cardiac failure, or uncontrolled hypertension were excluded. All the remaining patients were asked to volunteer for the study, the purpose and design of which were explained to them. Informed consent was obtained from 41 patients, but before the start of treatment seven withdrew their consent, three did not fulfil the entry criteria with regard to serum lipid concentration at control examination, and one died. Moreover, two patients who underwent angiography again after two years declined the final examination and were excluded. Thus the final series comprised 28 patients (table I), of whom only two were women.
CONTROLS
A non-randomised control group was formed from patients with coronary disease participating in another prospective study carried out at the same time at the same hospital.20 This other trial compared the effects of coronary bypass surgery with those of medical treatment on progression and outcome of coronary artery disease in men aged below 65. The entry criteria had included angina pectoris, a positive exercise test, and stenoses of more than 50", in at least two coronary arteries. One hundred patients had then been randomly assigned to receive either medical treatment or bypass surgery, and the surviving subjects underwent coronary angiography again after five years.20 Among the 50 patients randomly allocated to receive medical treatment 20 men had hyperlipidaemia by the criteria given above for our study and were not receiving any diet or drugs that lowered lipid concentrations. These men served as controls for the present study. Table I gives their baseline data and shows that patients and controls were largely comparable for major risk factors and also for degree of coronary lesions at entry. For some reason more patients than controls had a history of myocardial infarction or hypertension.
SCHEDULE OF TREATMENT FOR PATIENTS
Diet and drugs were used to produce maximal reduction of the raised cholesterol or triglyceride concentrations. Patients with hypercholesterolaemia were instructed to receive a diet containing roughly 300' of energy as fat with a ratio of polyunsaturated to saturated fats of about 1:1. Intake of cholesterol was limited to less than 300 mg a day. Subjects with raised triglyceride concentrations were also advised to reduce their consumption of saturated fats and to increase their intake of vegetable oils and fish. Overweight subjects received instructions for weight reducing diets. All instructions were given by a dietitian, whom the patients visited at least twice during the first year of the trial. The serum lipid and lipoprotein concentrations were measured, and the patients were seen by one of us (PV) every six weeks. If the diet did not reduce the total cholesterol concentration to less than 6-0 mmol/l (232 mg/100 ml) and total triglyceride concentration to less than 1 6 mmol/l (142 mg/100 ml) clofibrate was started at a daily dose of 2 0 g. If the correct concentrations were still not achieved 1 5-2-5 g nicotinic acid/day was added.
Adjustment of drugs and diets was stopped after one year, and the patients continued with the best combination for the remaining six years. During this time the serum lipid and lipoprotein concentrations, body weight, and blood pressure were measured every four months. The blur and film and folio blur showed an accuracy of 0 4 mm for the measurements of luminal diameters. Seven coronary arteries were analysed for each patient. In addition, the proximal, middle, and distal segments of three main epicardial arteries were analysed separately. The obstruction was estimated as the proportional reduction in the luminal diameter. The progression of coronary lesions at repeat angiography was assessed by one of us (MV) without any knowledge of the clinical or laboratory data. The progression was measured in two different ways. Firstly, the total increase in proportional luminal narrowing was calculated for each patient; thus an obstruction increasing from 50 to 75 O in one vessel or segment and from 25 to 50°O in another gave a total increase in obstruction of 50"0. Progression was said to be present if the luminal narrowing at a lesion had increased by a minimum of 20% or if a subtotal obstruction had advanced to total occlusion. Secondly, the number of major arterial segments showing progression was counted and related to the number of segments at risk for progression. Segments with complete occlusion at the first examination and those distal to the occlusion were not taken to be at risk for further progression, and their number was subtracted from the total number of arterial segments counted to get the number of segments at risk.
Initial angiography was done in 30 patients and 20 controls. Thirty patients were examined again at two years, but two declined the third angiography and were excluded. Four patients died before the end of the study; for them the results of the examination at two years were used. For all the others the assessment of progression was carried out from the results of angiography at seven years only. The significance of differences between the two groups was tested by either unpaired t test or X2 test with the Yates correction.
Results
The distribution of risk factors for coronary heart disease was fairly similar at entry for patients and controls (table I) . If anything, the patients had higher initial scores for risk factors than the controls as more of them had a history of myocardial infarction or hypertension. The initial mean plasma triglyceride concentration was also higher in the patients than controls, but the difference was not significant. In contrast, more controls than patients were cigarette smokers. The groups did not show any significant differences in the severity of the initial angiographic state assessed by the number and degree of arterial lesions.
The treatment to reduce lipid concentrations resulted in a significant decline in plasma cholesterol and triglyceride concentrations in the patients during the first year, the effect being sustained for the whole seven years of the trial. The average reductions in cholesterol and triglyceride concentrations were 18% and 38%, respectively. The LDL cholesterol concentration was reduced by an average of 19%, and the mean HDL cholesterol concentration was 10% higher during treatment than at entry. Blood pressure in all the patients was within the normal range at the beginning of and throughout the study. Despite the instructions for reducing weight the mean body weight of the 24 patients who were still alive at seven years increased slowly during the trial, being at the end 4% higher than the initial value (p<0-01); it increased in 18, was constant in three, and fell in three. Significant changes did not occur in the serum lipid concentrations of the 13 controls still alive at five years. Follow up data were not available for the seven controls who died during the five years of observation. Conversion: SI to traditional units-Cholesterol: 1 mmol/l z 38-7 mg/100 ml. Triglyceride: 1 mmol/l z 88-6 mg/100 ml.
achieved in every case. The controls were men with hyperlipidaemia participating in another prospective study carried out during the same period but aimed at comparing medical and surgical treatments. 20 The patients in this other study received conventional symptomatic treatment, but they were not given any dietary advice or drugs to reduce lipid concentrations. The patients and controls were largely comparable at entry, having roughly similar levels of risk factors and degrees of coronary atherosclerosis. The comparison of the angiographic progression between the two groups may therefore be thought to be valid, though not ideal. All clinical and angiographic findings of the present study suggest that treatment of hyperlipidaemia retarded the progression of'coronary atherosclerosis. The patients, who received this treatment, differed favourably from the controls in survival, course of anginal symptoms, physical performance, increase in the degree of coronary narrowing, and number of coronary arterial segments showing progression. Any exact comparison of the results with previously published data on the "natural" course of coronary atherosclerosis is difficult because most angiographic follow up studies have been retrospective, of shorter duration, and biased by a high incidence of case selection. The cardiac survival rate of 89% in seven years in our patients was much higher than that generally reported for patients with coronary disease of two or three vessels. Thus the corresponding figure from a recent study of a large, medically treated group of patients with severe coronary atherosclerosis was about 45% .2f In two prospective angiographic studies the five year survival rates were 69%27 and 800%.20 The proportion of separate arterial segments showing increased obstruction depends on the initial degree of narrowing.27 The findings reported so far have in general varied between 20 and 30% during a five year follow Up22 27 28; the figure of 10-13% in seven years found among our patients who responded well to treatment for hyperlipidaemia compare favourably with these.
The study also showed that the average angiographic progression was least in the patients with the lowest cholesterol, triglyceride, and VLDL plus LDL cholesterol concentrations during treatment and in those with the highest HDL cholesterol concentration. The absence of an association between progression and LDL cholesterol concentration was an unexpected finding that remains without adequate explanation. In follow up studies of patients with coronary disease in whom there is no intervention the association of angiographic progression with hyperlipidaemia has varied.28 29 The results agree with previous observations on retardation of progression of femoral atherosclerosis by treatment of hyperlipidaemia.1 30 Peripheral atherosclerosis seems to be more amenable to prevention and even to regression of the lesions than coronary disease as significant effects on peripheral atherosclerosis have already been detected within one to one and a half years of the start of treatment to lower lipid concentrations.'2 15 30 Less advanced coronary artery disease may, however, be more responsive to measures to lower lipid concentrations than the coronary disease of the patients in this study, who were all selected on the basis of severe symptomatic coronary atherosclerosis, in which many of the lesions had probably already reached an irreversible stage. The results are, however, encouraging and suggest that treatment to lower lipid concentrations may be more effective in preventing coronary heart disease than the previously disappointing results of some prevention trials have suggested." Indeed, the present results show that effective treatment of hyperlipidaemia is worth while, even in the stage of secondary prevention of coronary artery disease, and are consistent with the positive result recently reported from an extensive primary prevention trial using cholestyramine. 8 EAN was supported by grants from the Finnish Medical Research
